On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo
Regeneron and Sanofi $SNY aim to field the sixth new entry in the PD-1/L1 space next year, and like their rivals they have some big plans for followup approvals in a rush to command new market niches.
This morning Regeneron $REGN announced that it will pursue a combination program matching its checkpoint cemiplimab with an HPV16-targeting drug from the Dutch biotech ISA for cervical and head-and-neck cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.